73 results for 2000, Patent

  • Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy

    Rewcastle, Gordon; Gamage, Swarnalatha; Flanagan, JU; Giddens, Anna; Tsang, KY (2014-07-08)

    Patent
    The University of Auckland Library

    Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

    View record details
  • 5-Substituted-4-[(substituted phenyl)amino]-2-pyridone derivatives

    Black, Shannon; Kaufman, MD; Ortwine, DF; Plummer, MS; Quin, J; Rewcastle, Gordon; Shahripour, AB; Spicer, Julie; Whitehead, CE (2007)

    Patent
    The University of Auckland Library

    The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

    View record details
  • Methods of increasing radiosensitivity using inhibitors of trefoil factor 1 (TFF1)

    Lobie, Peter; Perry, Johanna (2012)

    Patent
    The University of Auckland Library

    The invention relates generally to the use of inhibitors of TTF1 to increase radiosensitivity of tumors and other cells. The invention provides methods of inhibiting proliferation or survival of a tumor cell; methods of treating, delaying the progression of, preventing a relapse of, or alleviating a symptom of a cancer or other neoplastic condition; methods increasing sensitivity of a tumor cell to radiotherapy; methods of enhancing or supplementing an anti-cancer therapy in a subject that is receiving or has been administered radiotherapy; and methods of inhibiting one or more activity or function of a TFF1 - stimulated cancer stem cell.

    View record details
  • Effects of Glycyl-2-methylprolylglutamate on Neurodegeneration

    Gluckman, Peter; Thomas, GB; Guan, J; Dragunow, M; Anand, Ashmit; Kerlero de Rosbo, N; Sieg, F; Brimble, Margaret (2007-12-27)

    Patent
    The University of Auckland Library

    This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.

    View record details
  • Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate

    Gluckman, Peter; Brimble, Margaret; Wilson, D; Tortella, FC; Williams, AJ; Xi-Chun, ML; Hartings, JA; Gryder, D (2010-05-11)

    Patent
    The University of Auckland Library

    Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury.

    View record details
  • Neuroprotective Bicyclic Compounds and Methods for their Use

    Brimble, Margaret; Guan, Jian; Sieg, Frank (2005-03-17)

    Patent
    The University of Auckland Library

    Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

    View record details
  • Pyrazolo[1,5-a]pyridines and their use in cancer therapy

    Kendall, JD; Marshall, Andrew (2009)

    Patent
    The University of Auckland Library

    Phosphoinositide-3-kinases (PI3Ks) are a group of lipid kinases which phosphorylate the 10 3-hydroxyl of phosphoinositides. They are split into three classes (Class I, II and Ill) and play an important role in cellular signalling [Stephens et al., Curr. Opin. Pharmacal. 2005, 5, 357]. The Class I enzymes are further split into Class Ia and lb based on their mechanism of activation; the Class Ia PI3Ks are heterodimeric structures consisting of a catalytic subunit (p11 Oa, p11 013 or p11 0~) in complex with a regulatory p85 subunit, while 15 the class-IB PI3K (p11 Oy) is structurally similar but lacks a reguiatory subunit linking and instead is activated by 13v subunits of heterotrimeric G-proteins [Walker et al,. Moi.Ce/1., 2000, 6, 909]. PI3Ks play a variety of roles in normal tissue physiology [Foukas & Shepherd, Biochem. 20 Soc. Trans., 2004,32, 330; Shepherd,Acta Physiol. Scand,. 2005, 183, 3], with p110a having a specific role in cancer growth, p11 013 in thrombus formation mediated by integrin aul33 [Jackson et al., Nat. Med., 2005, 11, 507], and p11 Oy in inflammation, rheumatoid arthritis [Camps et al., Nat. Med., 2005, 11, 936] and other chronic inflammation states [Barber et al., Nat. Med., 2005, 11, 933]. The PI3K enzymes produce phosphoinositide 25 3,4,5-triphosphate (PIP3) from the corresponding diphosphate (PIP2), thus recruiting AKT (protein kinase B) through its PH domain, to the plasma membrane. Once bound, AKT is phosphorylated and activated by other membrane bound kinases, and is central to a cascade of events that lead to inhibition of apoptosis [Berrie, Exp. Opin. Invest. Drugs, 2001, 10, 1085].

    View record details
  • Neural Regeneration Peptides and Methods for their Use

    Sieg, F; Brimble, Margaret; Muir, Victoria (2010-05-27)

    Patent
    The University of Auckland Library

    Embodiments of this invention include novel peptides that can promote survival of neurons and other cell types. Other embodiments of this invention include the methods for the use of peptides to promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation, neuronal survival and/or trophoblast proliferation, trophoblast migration and trophoblase survival. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly or indirectly via a replicable vehicle. NRP compounds can be formulated into pharmaceutically acceptable dosage forms for therapeutic use. Kits containing pre-determined doses of an NRP can be used to conveniently store, prepare and administer an NRP to a subject in need thereof.

    View record details
  • Marker assisted selection of a mammalian subject for desired phenotype

    Davis, S; Lehnert, K; Berry, SDK; Snell, Russell; Beattie, EM (2011)

    Patent
    The University of Auckland Library

    The present invention provides methods of genotyping mammalian subjects for desired lactoferrin phenotypes by determining the lactoferrin genotype of the subject. The invention particularly provides methods wherein the presence or absence of the T allele or the C allele at the 30126 T/C polymorphism, of the A allele or the G allele at the 7447 A/G polymorphism, or of the C allele or the G allele at the -7 G/C polymorphism in the bovine Lf gene, is associated with increased or decreased lactoferrin production or secretion, including increased or decreased milk or colostrum Lf content.

    View record details
  • Jet injector use in oral evaluation

    Hunter, IW; Chen, Y; Hogan, NC; Ruddy, BP (2012)

    Patent
    The University of Auckland Library

    A tooth treatment device includes a detector that detects a marker of oral health and a fluid ejector that ejects fluid against teeth in response to the detected marker. The device can include a housing configured to be held on hand, the fluid ejector being positioned at an end of the housing. The fluid may include a liquid, a medicant, a cleansing solution, cleaning particles, or any combination thereof. The medicant can include any combination of a chelating agent, fluoride, a fluorescent dye, a bacterial specific probe, and a biochemical specific biomarker. Further, the device can include a servo controller controlling pressure of ejected fluid in response to the detected marker and a sensed surface condition, latter including for example, a mechanical property of tissue. The device may include a pressure sensor that senses pressure of the fluid in the ejector. Also included may be a distance sensor that senses distance of the ejector from a tissue surface. The surface condition may be sensed using the sensed pressure, sensed distance, or any combination thereof. In some embodiments, the fluid ejector comprises a stationary magnet assembly providing a magnetic field and a coil assembly, slidably disposed with respect to the magnet assembly, the coil assembly driving ejection of the fluid jet. A method of tooth treatment includes detecting a marker of oral health and controlling ejection of a fluid jet against the tooth responsive to the detected marker. In some embodiments, detecting the marker includes detecting plaque and the ejection is controlled to clean the plaque. Detecting the marker can include collecting a sample from an oral cavity.

    View record details
  • Cascaded Raman Laser

    Martinelli, C; Leplingard, F; Sylvestre, T; Vanholsbeeck, Frederique; Emplit, P (2006-02-07)

    Patent
    The University of Auckland Library

    A cascaded Raman laser (10) has a pump radiation source (12) emitting at a pump wavelength λp, an input section (14) and an output section (16) made of an optical medium. Each section (14, 16) comprises wavelength selectors (141, 142, . . . , 145 and 161, 162, . . . , 165) for wavelengths λ1, λ2, . . . , λn−k, where n≧3, λp< . . . <λn and λn−k+1, λn−k+2, . . . , λn being k≧1 emitting wavelengths of the laser (10). The laser further comprises an intracavity section (18) that is made of a non-linear optical medium, has a zero-dispersion wavelength λ0 and is disposed between the input (14) and the output (16) section. The wavelengths λ1, λ2, . . . , λn−k of the wavelength selectors (141, 142, . . . , 145 and 161, 162, . . . , 165) and the zero-dispersion wavelength λ0 of the intracavity section (18) are chosen such that energy is transferred between different wavelengths by multi-wave mixing.

    View record details
  • Methods for producing neuronal cells and uses thereof

    Green, Colin; Sherwin, Trevor; Chang, CYA (2010)

    Patent
    The University of Auckland Library

    Methods for producing neuronal cells, methods of treating or preventing ophthalmic diseases or conditions or of promoting recovery from an ophthalmic therapy, and methods of treating or preventing neurological diseases or conditions or of promoting recovery from a neurological therapy are provided. The methods involving treating ophthalmic cells, particularly corneal cells, with insulin, epidermal growth factor and fibroblast growth factor 2 for a period sufficient to trans-differentiate the cells to neuronal cells.

    View record details
  • Quinoline derivatives for modulating DNA methylation.

    Brooke, Darby; Phiasivongsa, P; Denny, WA; Gamage, S; Bearss, DJ; Vankayalapati, H; Redkar, SG (2009)

    Patent
    The University of Auckland Library

    (EN)Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders. (FR)Cette invention concerne des dérivés de quinoline, en particulier des dérivés de 4-anilinoquinoline. Ces dérivés de quinoline peuvent être utilisés dans la modulation de la méthylation de l'ADN, par exemple dans l'inhibition effective de la méthylation de la cytosine en position C-5, par exemple par une inhibition sélective de l'ADN méthyltransférase DNMT1. L'invention concerne par ailleurs des procédés permettant de synthétiser plusieurs dérivés de 4-anilinoquinoline et de moduler la méthylation de l'ADN. L'invention concerne également des procédés permettant de formuler et d'administrer ces composés ou ces compositions pour traiter des pathologies comme le cancer et les troubles hématologiques.

    View record details
  • Methods and compositions for increasing storage-life of fruit

    Atkinson, R; Schaffer, Robert; Gunaseelan, K; Schroeder, R (2010)

    Patent
    The University of Auckland Library

    The invention provides methods and compositions for producing plants with fruit having increased post-harvest storage life, the method comprising reducing the expression or activity in the plant, of a polypeptide with the amino acid sequence of SEQ ID NO: 1(Malus domestica polygalaturonase, MdPG1), or a variant of the polypeptide. The invention provides host cells, plant cells and plants transformed with the polynucleotides of the invention. The invention also provides methods for selecting plants with fruit having increased postharvest storage life. The invention also provides plants produced and selected by the methods of the invention.

    View record details
  • Impaired wound healing compositions and treatments

    Becker, DL; Green, Colin; Duft, BJ (2011-11-22)

    Patent
    The University of Auckland Library

    Methods, compounds, compositions, kits and articles of manufacture comprising one or more gap junction modulating agents for treatment of wounds that do not heal at expected rates, including chronic wounds, delayed healing wounds, incompletely healing wounds, and dehiscent wounds in a subject in need thereof.

    View record details
  • Diagnostically and audibly responsive computer learning memory game and system provided therefor

    Dowrick, Peter (2006)

    Patent
    The University of Auckland Library

    A diagnostically and audibly responsive computer learning memory game works with small children and other persons in teaching them to read. Square or rectangular tiles to be uncovered are displayed upside down, concealing words to be matched with words or words to be matched with phrases or visual pictures or audible sounds, objective is to find matching cards. The computer game matches the cards or tiles with sight words that the user is learning to read from a word list. The user must remember where a correct word of the word pairs is located. The user must read word orally, if not, the computer will prompt the user with a clue (such as the beginning sound of a word) until the user answers. If nothing is heard, the user is told the answer. The system has a built-in recording of a library of selected words, phrases, pictures or audible sounds. The computer can sense that user is silent (with a default of no sound). If a wrong word is uttered, the system can remain silent or correct..

    View record details
  • Selection of animals for desired milk and/or tissue profile

    Lehnert, K; Berry, SD; Snell, Russell; Macgibbon, AKH; Spelman, R; Ankermist-Udy, A (2011)

    Patent
    The University of Auckland Library

    The present invention is directed to mutations in the DGAT1 gene that produce an advantageous milk, tissue and/or growth rate profile in animals carrying the mutations. The present invention is also directed to methods of identifying animals carrying the mutations in order to facilitate the selection of animals with altered milk, tissue and/or growth rate traits.

    View record details
  • Directly photodefinable polymer compositions and methods thereof

    Elce, E; Bell, A; Knapp, B; Ng, H; Rhodes, LF; Shick, R; Zhang, W; Dimenna, W; Jayaraman, S; Jin, Jianyong; Puthenkovilakom, RR; Ravikiran, R; Wu, X; Takeuchi, E (2011)

    Patent
    The University of Auckland Library

    A polymer includes a first type of repeat unit represented by Formula I, where X is selected from -CH2-, -CH2-CH2-, or -O-; m is an integer from 0 to about 5; and where for the first type of repeat unit one of R1, R2, R3, and R4 is one of a maleimide containing group and for the second type of repeat unit one of R1, R2, R3, and R4 is a hindered aromatic group, a C8 or greater alkyl group, a C4 or greater halohydrocarbyl or perhalocarbyl group, a C7 or greater aralkyl group, or a heteroatom hydrocarbyl or halohydrocarbyl group.

    View record details
  • Polypeptides and Polynucleotides for Artemin and related Ligands, and Methods of Use Thereof

    Liu, Dongxu; Lobie, Peter (2008)

    Patent
    The University of Auckland Library

    The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial cancer, lung cancer, stomach cancer, liver cancer, and others, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof. Particularly encompassed are inhibitors of Artemin and/or related ligands, and uses for these inhibitors.

    View record details
  • Improvements for Cochlear Implants

    Bradley, AP; Petoe, Matthew; Wilson, WJ (2010)

    Patent
    The University of Auckland Library

    The invention relates to a method of generating a place-frequency map for accurate positioning of a cochlear implant whereby the place-frequency map is used to relate a physical position of the cochlear implant to a tonotopic map of the basilar membrane/spiral ganglion. The invention also relates to a method of electrically positioning of an already inserted cochlear implant within the cochlea to provide stimuli to only the parts of the cochlea that have reduced or no residual hearing.

    View record details